Brokerages expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report $550,000.00 in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Global Blood Therapeutics’ earnings, with the lowest sales estimate coming in at $30,000.00 and the highest estimate coming in at $1.09 million. The business is expected to report its next earnings report on Wednesday, February 26th.
On average, analysts expect that Global Blood Therapeutics will report full-year sales of $550,000.00 for the current year, with estimates ranging from $30,000.00 to $1.09 million. For the next fiscal year, analysts forecast that the firm will report sales of $45.39 million, with estimates ranging from $21.10 million to $68.99 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.04). During the same period in the previous year, the company posted ($0.83) EPS.
GBT has been the subject of a number of recent analyst reports. Cowen set a $83.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on shares of Global Blood Therapeutics from $58.00 to $79.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Oppenheimer reissued a “buy” rating and issued a $100.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of Global Blood Therapeutics in a research note on Wednesday, October 9th. Finally, William Blair reiterated a “buy” rating on shares of Global Blood Therapeutics in a research report on Wednesday, December 18th. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $95.19.
In related news, insider Tricia Borga Suvari sold 3,327 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $48.45, for a total transaction of $161,193.15. Following the completion of the transaction, the insider now owns 12,386 shares of the company’s stock, valued at $600,101.70. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Joshua Lehrer-Graiwer sold 11,593 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $67.19, for a total transaction of $778,933.67. Following the completion of the transaction, the insider now directly owns 312 shares of the company’s stock, valued at approximately $20,963.28. The disclosure for this sale can be found here. Insiders sold a total of 97,490 shares of company stock valued at $7,020,482 in the last three months. 4.30% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in GBT. Truvestments Capital LLC grew its position in Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock valued at $45,000 after purchasing an additional 300 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Global Blood Therapeutics by 133.3% during the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after buying an additional 400 shares in the last quarter. Quest Capital Management Inc. ADV purchased a new stake in Global Blood Therapeutics during the 3rd quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Global Blood Therapeutics by 16.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,814 shares of the company’s stock valued at $185,000 after buying an additional 549 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in Global Blood Therapeutics by 11.1% during the 2nd quarter. Prudential Financial Inc. now owns 5,623 shares of the company’s stock valued at $296,000 after buying an additional 560 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.
Shares of GBT stock traded down $0.47 on Monday, reaching $80.36. The stock had a trading volume of 394,043 shares, compared to its average volume of 816,753. Global Blood Therapeutics has a 12 month low of $43.69 and a 12 month high of $87.54. The firm has a market capitalization of $4.87 billion, a price-to-earnings ratio of -20.71 and a beta of 1.75. The firm’s 50-day moving average is $79.78 and its two-hundred day moving average is $58.85. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.04.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Read More: Limitations of the P/E Growth ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.